Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | HRH1 | P35367 | 2/20 | 0.48 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5165935 | 0.90 | HDAC1 (0.63) | LTA4HHDAC1CHRM4HRH3JAK2 | |
| SCHEMBL5167316 | 0.88 | HDAC1 (0.48) | LTA4HHDAC1CNR2CHRM4HRH3 | |
| SCHEMBL5167418 | 0.87 | NPC1 (0.59) | LTA4HHDAC1HRH3HRH1HRH2 | |
| SCHEMBL1911332 | 0.84 | LTA4H (0.60) | LTA4HHDAC1CHRM4CYP2D6 | |
| SCHEMBL13634431 | 0.84 | LTA4H (0.60) | LTA4HHDAC1CHRM4CYP2D6 | |
| SCHEMBL13024536 | 0.84 | LTA4H (0.60) | LTA4HHDAC1CHRM4CYP2D6 | |
| SCHEMBL5167424 | 0.82 | HDAC1 (0.55) | LTA4HHDAC1CHRM4HRH3JAK2 | |
| SCHEMBL5165601 | 0.80 | HDAC1 (0.56) | LTA4HHDAC1CHRM4HRH3HRH1 | |
| SCHEMBL5166411 | 0.80 | GRM2 (0.56) | LTA4HHDAC1CHRM4HRH3HRH1 | |
| SCHEMBL5164995 | 0.80 | HDAC1 (0.53) | LTA4HHDAC1CHRM4HRH3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771438-A1 | 1-3 SUBSTITUTED CYCLOAMINO DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-04-11 | — | — | EP | claimed |
| WO-2006011042-A1 | 1, 3 SUBSTITUTED CYCLOAMINO DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20060014733-A1 | Histamine-3 agonists and antagonists | PFIZER INC | 2006-01-19 | — | — | US | claimed |
| EP-1771438-A1 | 1-3 SUBSTITUTED CYCLOAMINO DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006011042-A1 | 1, 3 SUBSTITUTED CYCLOAMINO DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060014733-A1 | Histamine-3 agonists and antagonists | PFIZER INC | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014733-A1 | Histamine-3 agonists and antagonists | HRH3, HRH4, HRH2 | LTA4H 395/4885HDAC1 1532/4885CNR2 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.